Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials

[1]  R. Kurzrock,et al.  Liquid biopsy: current technology and clinical applications , 2022, Journal of Hematology & Oncology.

[2]  P. Xing,et al.  Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2) , 2022, BMC Medicine.

[3]  L. Ouyang,et al.  Emerging strategies to overcome resistance to third-generation EGFR inhibitors , 2022, Journal of Hematology & Oncology.

[4]  X. Yi,et al.  Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer , 2022, Cancer discovery.

[5]  Joe Y. Chang,et al.  Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  P. Jänne,et al.  Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Ying Cheng,et al.  Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  A. Tsao,et al.  Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Jänne,et al.  Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. , 2021, The New England journal of medicine.

[10]  J. Roth,et al.  Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer , 2021, Journal for ImmunoTherapy of Cancer.

[11]  Y. Lou,et al.  Targeted therapy in advanced non-small cell lung cancer: current advances and future trends , 2021, Journal of Hematology & Oncology.

[12]  D. Aust,et al.  Brief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Gregory Riely,et al.  Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. , 2021 .

[14]  Yungui Wang,et al.  P86.02 Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study , 2021 .

[15]  W. Feng,et al.  Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  C. Criscitiello,et al.  Antibody–drug conjugates in solid tumors: a look into novel targets , 2021, Journal of Hematology & Oncology.

[17]  Jianxing He,et al.  Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma , 2021, Theranostics.

[18]  Yuankai Shi,et al.  Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) , 2020, Journal of Hematology & Oncology.

[19]  Erin L. Schenk,et al.  LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions , 2020 .

[20]  Jianxing He,et al.  Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Lou,et al.  Emerging therapeutic agents for advanced non-small cell lung cancer , 2020, Journal of Hematology & Oncology.

[22]  C. Rolfo,et al.  HER2 Mutations in Non-Small Cell Lung Cancer: A Herculean Effort to Hit the Target. , 2020, Cancer discovery.

[23]  J. Zhao,et al.  Targeting HER2 Alterations in Non-Small-Cell Lung Cancer: A Comprehensive Review. , 2020, JCO precision oncology.

[24]  Y. Bang,et al.  HER2-targeted therapies — a role beyond breast cancer , 2019, Nature Reviews Clinical Oncology.

[25]  A. Drilon,et al.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Anshul Kundaje,et al.  The ENCODE Blacklist: Identification of Problematic Regions of the Genome , 2019, Scientific Reports.

[27]  H. Ji,et al.  HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Abhijit A. Patel,et al.  Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA , 2018, Clinical Cancer Research.

[29]  S. Toyooka,et al.  A Phase II Study of Trastuzumab Emtansine in HER2‐Positive Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  M. Berger,et al.  Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Mazières,et al.  Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  O. Hofmann,et al.  VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research , 2016, Nucleic acids research.

[33]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[34]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[35]  Gabor T. Marth,et al.  Haplotype-based variant detection from short-read sequencing , 2012, 1207.3907.

[36]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[37]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[38]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[39]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..